Telomir Pharmaceuticals, Inc. 8-K Filings

Telomir Pharmaceuticals, Inc. (TELO) reported the results of its 2026 Annual Meeting of Stockholders held on September 11, 2026. Stockholders owning 47,129,480 shares, or 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date, were represented, constituting a quorum.

All three proposals were approved, including the election of directors Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D. For example, Aminov received 43,363,662 votes for and 93,927 withheld, with 3,671,891 broker non-votes. Stockholders also ratified Salberg & Company, P.A. as independent registered public accounting firm for 2026 with 46,998,583 votes for, and approved a possible adjournment of the meeting with 44,841,042 votes for.

Telomir Pharmaceuticals, Inc. (TELO) reported new preclinical data showing that its lead candidate Telomir-Zn inhibited cell growth in both human and canine osteosarcoma cell lines (HOS, D17, Abrams) at similar low concentrations. These in‑vitro findings support further translational work in osteosarcoma.

The company’s primary clinical effort remains a Phase 1/2 program of Telomir-Zn in advanced or metastatic triple-negative breast cancer

Telomir Pharmaceuticals, Inc. reported that a peer-reviewed preclinical study of its lead candidate Telomir-Zn was published in the Journal of Oncology Research and Therapy, Volume 11, Issue 3. The study shows Telomir-Zn depletes intracellular iron to inhibit JmjC histone demethylases (KDMs), enzymes overexpressed in aggressive cancers, leading to tumor-suppressor gene reactivation and reduced tumor growth in prostate and triple-negative breast cancer (TNBC) models.

In TNBC models, Telomir-Zn reduced primary tumor size and significantly curtailed metastatic spread in an HCC1806 model, and showed synergistic tumor reduction when combined with paclitaxel in BT-549 xenografts, while one TNBC model (MDA-MB-231) did not respond. The compound killed iron-dependent TNBC cells at low concentrations while sparing normal cells at concentrations more than 50-fold higher, suggesting a favorable selectivity window. These findings support advancement of Telomir-Zn into a planned Phase 1/2 clinical trial in TNBC under an active IND.

Telomir Pharmaceuticals filed an 8-K to share new preclinical data on its lead program, Telomir-Zn. A peer-reviewed paper in Biomedicine & Pharmacotherapy reports that Telomir-Zn improved glucose metabolism and insulin resistance in a diet-induced zebrafish model of Type 2 diabetes.

The study showed dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin, and HOMA-IR, with HOMA-IR scores falling from about 10–12 to around 3 after 14 days of treatment. The company notes this is its second Telomir-Zn publication in 2026 and says the findings further support its metal-homeostasis mechanism, which also underpins its FDA-cleared Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.

Telomir Pharmaceuticals, Inc. reported a leadership change in its finance function. Effective June 6, 2026, Alan Weichselbaum will no longer serve as Chief Financial Officer, with the company stating his departure is not due to any disagreement over operations, policies, or practices. On June 3, 2026, the board appointed Andriy Mushak, a Massachusetts-licensed CPA with over 20 years of SEC reporting and audit experience, as fractional Chief Financial Officer. Mushak will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will receive $6,000 per month. The company notes he has no disclosable related-party relationships or transactions with current executives or directors.

Telomir Pharmaceuticals, Inc. filed an 8-K describing a press release about a new peer-reviewed preclinical study of its lead candidate Telomir-1 (Telomir-Zn) in Wilson’s disease. The study, published in Advances in Redox Research, used cellular systems and an ATP7B-deficient zebrafish model.

Telomir-Zn showed dose-dependent benefits across multiple endpoints, including reduced copper-associated oxidative stress, lower hepatic copper burden, improved liver injury biomarkers such as ALT, AST and bilirubin, attenuated intracellular calcium dysregulation, better locomotor performance, reduced hepatorenal tissue degeneration, and improved survival.

This is Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data supporting its mechanism of modulating intracellular copper and redox pathways. The company notes these pathways are also relevant to its Telomir-Zn program in Triple-Negative Breast Cancer, which has FDA IND clearance for a Phase 1/2 trial.

Telomir Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn, the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer.

The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the recommended Phase 2 dose. Phase 2 will assess preliminary efficacy, with objective response rate as the primary endpoint and duration of response, progression‑free survival, overall survival, and safety as key secondary endpoints.

The trial will feature an extensive translational biomarker program to study epigenetic regulation, gene expression, histone modification, and telomere‑related biology, aiming to link target engagement and biomarker changes with clinical outcomes in triple‑negative breast cancer.

Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, issuing 34,389,710 restricted shares of common stock to TELI’s former shareholders. The share count was based on an exchange ratio derived from independent third-party valuations of both companies.

At closing, Bayshore Trust contributed $1 million to Telomir and entered into an option to pay up to $4 million more for Telomir shares if milestones are met, including FDA acceptance of an Investigational New Drug application and initiation of a Phase 1/2 study for Telomir-1. The deal consolidates all global rights to Telomir-1 under Telomir, giving it full control over development and potential commercialization across major international markets.

Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is closed, meaning Telomir’s listing status related to this meeting requirement is no longer in question.

Telomir Pharmaceuticals, Inc. submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate Telomir-1 (Telomir-Zn) to treat advanced and metastatic triple-negative breast cancer (TNBC). If the IND is cleared, the company plans a Phase 1/2 trial of Telomir-1 as an oral monotherapy.

The Phase 1 portion is expected to use a standard 3+3 dose-escalation design to assess safety, tolerability, dose-limiting toxicities, and select a recommended Phase 2 dose. Phase 2 is expected to use a Simon two-stage design focused on objective response rate as the primary endpoint.

Telomir-1 is described as a first-in-class metal-modulating epigenetic therapy designed to reduce redox-active iron and increase zinc availability, inhibiting iron-dependent epigenetic enzymes such as histone demethylases. The company reports preclinical data showing reduced tumor growth and metastasis in TNBC models, iron-dependent tumor cell death in several human TNBC cell lines, and GLP safety studies with no treatment-related adverse or dose-limiting toxicities observed.

Telomir Pharmaceuticals reported that shareholders approved several major items at the Annual Meeting held on March 23, 2026. They authorized issuing shares of common stock and other securities for the acquisition of Teli Pharmaceuticals that will exceed 20% of the company’s pre-transaction common shares. Shareholders also amended the 2023 Omnibus Incentive Plan, lifting the share reserve from 6,500,000 to 11,500,000 and permitting repricing of options and stock appreciation rights at the plan administrator’s discretion. In addition, the bylaws were amended to reduce the quorum requirement for shareholder meetings to one-third of eligible shares, all director nominees were elected, and the auditor ratification and other compensation-related proposals passed.

Telomir Pharmaceuticals, Inc. reported new preclinical in vitro results for its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (TNBC) cell lines. Telomir-Zn showed near-complete tumor cell mortality at 72 hours in the MDA-MB-468 model and significant partial reductions in viable tumor cells in the HCC70 and MDA-MB-231 models.

The company also found that adding supplemental iron reduced Telomir-Zn–induced tumor cell mortality, which it interprets as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity. Additional TNBC lines (BT-549 and HCC1806) are under evaluation, and a TNBC mouse xenograft study is being prepared in a mammalian system.

Telomir referenced earlier zebrafish xenograft work where Telomir-Zn achieved statistically significant reductions in tumor growth and metastasis in select TNBC models. It reiterated that it is continuing IND-enabling activities and anticipates submitting an Investigational New Drug application in the first quarter of 2026, after previously completing GLP safety and toxicology studies in rats and dogs without treatment-related adverse toxicity.

Telomir Pharmaceuticals, Inc. reported new preclinical cellular data on its lead investigational compound Telomir-1, studied as Telomir-Zn. In collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to rapidly and dose-dependently increase intracellular zinc and reduce labile ferrous iron within about 30 minutes, with effects sustained for two hours and without loss of cell viability.

The coordinated metal redistribution suggests a potential mechanism that may lower oxidative stress and support genomic and epigenetic stability, processes implicated in both cancer and aging. The company is advancing additional preclinical programs in triple-negative breast cancer and longevity models and currently plans to submit an Investigational New Drug application in the first quarter of 2026.

Telomir Pharmaceuticals, Inc. disclosed that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual shareholder meeting within twelve months after the end of their fiscal year. The company had planned to hold its annual meeting on December 30, 2025, but its preliminary proxy statement remains under SEC review.

Nasdaq’s notice does not immediately affect the listing or trading of Telomir’s common stock on the Nasdaq Capital Market. Telomir has until February 23, 2026 to submit a plan to regain compliance, and Nasdaq may grant additional time if it accepts that plan. After the SEC review is completed, Telomir expects to promptly hold its annual meeting and regain compliance and states it intends to take all necessary steps within the applicable cure period.

Telomir Pharmaceuticals reported new incentive arrangements for its Chief Executive Officer, Erez Aminov. Following a review of 2025 performance, the Compensation Committee approved a 2025 short‑term incentive payout of $400,000, based on operational execution, financing activities, and program advancement.

The Board also granted a $150,000 milestone award that will be paid only if the FDA accepts the Company’s future IND submission for its Telomir‑1 program; no IND has been submitted yet. In connection with the potential acquisition of TELI Pharmaceuticals, Inc., the Board approved a transaction advisory award equal to 3% of the total TELI transaction value, payable in cash, equity, or a mix, at the CEO’s election, with any equity vesting immediately at closing. In addition, the CEO’s base salary was set at $500,000 effective January 1, 2026, based on external benchmarking and advice from an independent compensation consultant.

Telomir Pharmaceuticals, Inc. reported favorable results from a full package of Good Laboratory Practice toxicology and safety pharmacology studies for its lead candidate, Telomir-1 (Zn-Telomir). The completed cardiovascular, respiratory, phototoxicity, and repeat-dose studies in in vitro systems and in rat and dog models showed Telomir-1 was generally well tolerated, with no treatment-related adverse or dose-limiting toxicities and only limited, reversible, non-adverse findings. In non-rodent dog studies, no test-article-related changes in blood pressure, heart rate, ECG parameters, or body temperature were seen after oral dosing, and oral studies showed consistent systemic exposure.

These results support advancement into first-in-human clinical trials, with no findings identified that would prevent clinical entry, subject to regulatory pathways. The company plans to submit an Investigational New Drug application in the first quarter of 2026 and aims to start first-in-human clinical studies in the first half of 2026 while continuing preclinical work in oncology and age-related diseases and preparing manuscripts and scientific conference submissions.

Telomir Pharmaceuticals, Inc. (TELO) announced new preclinical data on its investigational candidate Telomir-1 in prostate cancer models. In an in vitro study using androgen-responsive human prostate cancer LNCaP cells, Telomir-1 reduced prostate-specific antigen (PSA) levels in a dose-related manner. PSA is an FDA-recognized biomarker where higher levels generally indicate more active tumor behavior.

The company also highlighted prior mouse data in a PC3 xenograft model of aggressive, non-androgen-related prostate cancer, where Telomir-1 reduced tumor volume as a single agent, and in combination with paclitaxel achieved full tumor volume reduction without treatment-related mortality, while paclitaxel alone caused high mortality. Telomir continues preclinical development of Telomir-1 across oncology, aging biology, autism-related pathways and other age-associated conditions, and is advancing IND-enabling work toward a planned IND submission.

Telomir Pharmaceuticals, Inc. reported that Board member Craig Eagle resigned from the Board of Directors, effective November 14, 2025. The company states that his resignation was not due to any disagreement with Telomir, its management, or any other Board member. The Board expressed appreciation for his service. A copy of Mr. Eagle’s resignation letter is included as Exhibit 17.1 to this report.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) reported new preclinical results showing its investigational small molecule Telomir-1 killed aggressive human leukemia (HL60) cells in vitro. The compound produced a clear, dose-dependent reduction in leukemia cell viability in this widely used model of acute myeloid leukemia.

The company links these findings to earlier research where Telomir-1 markedly reduced intracellular Fe²⁺ levels in human cell systems, with stronger cell-penetrating, iron-lowering activity than the chelator Deferoxamine at the same concentrations. Telomir-1 has also been shown to reduce abnormal DNA methylation in tumor-suppressor genes such as STAT1, CDKN2A, MASPIN, RASSF1A, CASP8, and GSTP1, and to inhibit key lysine histone demethylase (KDM2, KDM5, KDM6) enzyme families. Together, these iron-modulating and epigenetic effects support Telomir’s broader oncology research program, which already includes models of triple-negative breast, pancreatic, and aggressive prostate cancers.

Telomir Pharmaceuticals filed an 8-K reporting new preclinical results for Telomir-1. In human keratinocyte (HaCaT) cells, Telomir-1 produced a strong, dose- and time-dependent reduction of intracellular ferrous iron (Fe²⁺), with greater effect than the FDA‑approved iron chelator Deferoxamine (DFO) under equivalent conditions.

The study used FerroOrange live-cell imaging and observed lower Fe²⁺ signal at three, six, and sixteen hours, indicating cell penetration and iron‑modulating activity at low concentrations. The company also noted a zinc‑formulated version, Telomir‑Zn, designed to exchange metal ions by binding excess reactive metals such as iron and copper while contributing zinc, a cofactor for enzymes tied to antioxidant defense and DNA stability. The findings support ongoing research into metal‑ion balance, oxidative stress, and epigenetic regulation in aging and degenerative disease.

Telomir Pharmaceuticals (TELO) announced new preclinical data on Telomir-1 in a mouse model of aggressive prostate cancer, focusing on DNA methylation changes in two defense genes, CASP8 (apoptosis) and GSTP1 (glutathione-based detoxification).

On Day 21, Telomir-1 was associated with reduced DNA methylation of both CASP8 and GSTP1 versus vehicle and chemotherapy, suggesting potential re-activation of apoptosis and detoxification-related gene functions. The combination of Telomir-1 and chemotherapy showed lower methylation than chemotherapy alone in this model. Rapamycin showed an initial reduction at Day 10 that partially rebounded by Day 21, while Telomir-1 continued a progressive, more sustained decrease. The company believes DNA-methylation control may be an important area of ongoing evaluation for Telomir-1 in oncology research.

Telomir Pharmaceuticals (NASDAQ: TELO) signed a binding LOI to acquire TELI Pharmaceuticals in a stock-for-stock deal, consolidating worldwide intellectual property and development rights to its lead candidate, Telomir-1.

The agreement includes up to $5 million in cash contributions from certain TELI shareholders: $1 million at closing, $2 million upon FDA acceptance of an IND, and $2 million upon initiation of a Phase 1/2 study. Shares tied to the $4 million in milestone contributions will be allocated at closing and issued upon receipt of each payment. Closing is not contingent on receiving the milestone funds.

The LOI imposes a six-month lockup on shares issued to TELI holders and is subject to due diligence, board and stockholder approvals, regulatory clearances, and definitive agreements. If completed, Telomir would hold unified global rights to Telomir-1, aiming to simplify development and partnering.

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.

The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.

Telomir Pharmaceuticals, Inc. reported new preclinical findings showing that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies. As Telomir-1 concentrations increased in human TNBC cell models, cancer cell survival dropped in a clear, concentration-dependent manner, and adding iron back restored cell growth, indicating the effect is tied to iron-dependent energy regulation.

The company explains that TNBC cells are highly metabolically active and rely heavily on iron, and that Telomir-1 appears to exploit this vulnerability while normal cells manage iron differently. Telomir-1 has also been shown previously to reset abnormal DNA methylation patterns, and the new data suggest its impact on TNBC may involve iron-dependent epigenetic enzymes linked to aggressive behavior and treatment resistance. Telomir plans to expand these studies to other cancer types and perform additional animal studies as it prepares an Investigational New Drug submission.

Telomir Pharmaceuticals, Inc. reported new preclinical findings for its lead investigational compound, Telomir-1, in aggressive prostate cancer models. The studies showed that Telomir-1 can reset abnormal DNA methylation and restore the function of two key tumor suppressor genes, MASPIN and RASSF1A, which are often silenced in cancer and are closely linked to metastasis and treatment resistance.

In an in vivo aggressive prostate cancer model, MASPIN was silenced by DNA hypermethylation, and Telomir-1 reversed chemotherapy-induced DNA methylation to restore MASPIN activity. Telomir-1 also reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. The company states that reactivating these genes may help restore natural tumor defenses, counteract chemotherapy-induced resistance, and limit cancer metastasis as part of its ongoing preclinical and IND-enabling development of Telomir-1.

Telomir Pharmaceuticals reported new in vitro pharmacology data for its lead candidate Telomir-1, showing that the drug potently inhibits three members of the KDM5 histone demethylase family. These enzymes help cancers and aging cells silence protective genes and activate harmful inflammatory pathways.

The company notes that Telomir-1 had already demonstrated activity against other histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A), while sparing broad acetyltransferases linked to systemic toxicity. In earlier in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressor genes such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.

Taken together, Telomir-1 is described as having broad-spectrum activity across DNA methylation and multiple histone demethylation pathways, supporting ongoing IND-enabling studies, GMP scale-up, and additional preclinical work in aggressive cancers and aging models.

Telomir Pharmaceuticals reported new preclinical results in aggressive human prostate cancer cell models showing that its investigational therapy Telomir-1 reverses DNA methylation–driven silencing of CDKN2A, a key tumor suppressor often described as the body’s natural “cell cycle brake.” In these PC3 xenograft models, Telomir-1 inhibited DNA hypermethylation of CDKN2A and outperformed both Rapamycin and chemotherapy on this measure.

The company notes that earlier data showed Telomir-1 also resets DNA methylation of STAT1, a master immune regulator. Together, the STAT1 and CDKN2A findings suggest Telomir-1 can reset epigenetic silencing across multiple tumor suppressor and immune pathways. Telomir is evaluating Telomir-1 in several aggressive cancer types and continues its pre-IND work, including CMC scale-up toward GMP production and IND-enabling studies ahead of a planned first IND submission.

Telomir Pharmaceuticals, Inc. completed an at-the-market equity offering on August 28, 2025, selling 1,550,000 shares of common stock in block trades to institutional investors at an average price of $1.87 per share. This generated gross proceeds of approximately $2.9 million before fees and expenses. The sales were executed through Rodman & Renshaw using the StockBlock platform and did not include any warrants.

Telomir Pharmaceuticals filed an update on new laboratory data for its lead preclinical drug candidate, Telomir-1, which targets the biology of cancer, aging, and age-related diseases. In in vitro studies run by Eurofins Discovery, Telomir-1 potently inhibited the histone demethylase UTX (KDM6A), an enzyme tied to abnormal DNA methylation patterns that can silence tumor suppressors and activate disease-driving genes. By blocking UTX, the compound showed potential to help reset faulty gene regulation.

The company notes prior findings that Telomir-1 inhibits other epigenetic enzymes FBXL10, FBXL11, and JMJD3, and can reactivate silenced tumor suppressors such as STAT1 and TMS1 in prostate cancer models. The new data also highlight selectivity: Telomir-1 showed no activity against the broad acetyltransferase GCN5L2 (KAT2A), which is associated with toxicity when inhibited. It did show low-level inhibition of Tankyrases (PARP5A and PARP5B), suggesting modest interference with Wnt/β-catenin “fuel line” signaling that cancers use for growth. Overall, the results support Telomir-1’s profile as a potential first-in-class epigenetic therapy with a dual mechanism of resetting DNA methylation pathways and modestly impacting Wnt/Tankyrase signaling.